Healthcare Industry News: Northwest Biotherapeutics
News Release - January 23, 2008
Michael L. Salgaller, Ph.D., Appointed Chief Operating Officer of Calibrant BiosystemsGAITHERSBURG, Md.--(HSMN NewsFeed)--Calibrant Biosystems, a biotechnology company specializing in proteomics, today announced the appointment of Dr. Michael Salgaller as its Chief Operating Officer, effectively immediately.
As COO, Dr. Salgaller will be responsible for the company’s worldwide development and operations, including ongoing drug development programs and external partnerships. In addition, he will work closely with Calibrant’s full executive team to guide the company’s overall business strategy and growth.
Dr. Salgaller, who was an advisor to Calibrant in 2005-2006, will report to Cheng Lee, Calibrant’s CEO. “Michael has been an important contributor to the Calibrant team in recent years, and we are excited to have him on board full-time,” said Cheng Lee, Calibrant’s CEO. “We all look forward to working closely together as the company continues to accomplish a number of exciting milestones in the area of personalized medicine.”
Dr. Salgaller comes to Calibrant with over 20 years scientific and business experience in therapeutics. Before joining Calibrant, he was on the investment team at Toucan Capital, a venture firm focused on early-stage life science investments. Prior to Toucan Dr. Salgaller was Vice President of Clinical and Research Affairs at Northwest Biotherapeutics, a publicly held cancer therapeutics company, where he lead the development of their vaccine platform. He has held a variety of senior management positions in biotechnology, and led a number of translational and clinical projects. He served as Senior Staff Scientist at the National Institutes of Health, and has consulted for various bio-pharma companies and disease foundations. Dr. Salgaller earned a PhD in Pathology from The Ohio State University, and was awarded a Biotechnology Fellowship at the National Cancer Institute.
About Calibrant Biosystems
Calibrant Biosystems is a Gaithersburg, MD biotechnology company specializing in targeted drug discovery from clinical tissue specimens. Calibrant’s advanced Gemini discovery platform, which is compatible with both fresh and formalin-fixed archival tissues, provides the unique ability to comparatively map protein networks between different cell types within a single tissue section. With an initial focus on monoclonal antibody drug development in oncology, Calibrant is leveraging the Gemini platform for the development of first-in-class therapeutics across a range of cancer indications. More information is available at www.calibrant.com.
Note: Gemini is a trademark of Calibrant Biosystems.
Source: Calibrant Biosystem
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.